Chapters

Transcript

Video

To what degree have you observed statin intolerance or resistance in patients with high risk CAD? What protocol do you employ to mitigate and/or manage statin intolerance? Where does the PCSK9 inhibitor fit into your sequencing strategy?

To what degree have you observed statin intolerance or resistance in patients with high risk CAD? What protocol do you employ to mitigate and/or manage statin intolerance? Where does the PCSK9 inhibitor fit into your sequencing strategy?

 


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Anne C. Goldberg, MD, FNLA, FACP, FAHA

Anne C. Goldberg, MD, FNLA, FACP, FAHA

Professor of Medicine
Division of Endocrinology, Metabolism & Lipid Research
Washington University in St. Louis
St. Louis, MO